Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6992678 | 0.82 | DRD4 (0.56) | — | |
| SCHEMBL7971718 | 0.82 | CCR3 (0.66) | ACHESLC6A2SLC6A4 | |
| SCHEMBL6219793 | 0.82 | DRD2 (0.63) | ACHESLC6A2SLC6A4 | |
| SCHEMBL4419110 | 0.81 | ADRA1D (0.64) | — | |
| SCHEMBL8825219 | 0.81 | ACHE (0.81) | ACHE | |
| SCHEMBL11803997 | 0.80 | ALDH1A1 (0.58) | ACHE | |
| SCHEMBL13901434 | 0.78 | ACHE (0.60) | ACHESLC6A4 | |
| SCHEMBL9232521 | 0.78 | HTR2A (0.67) | — | |
| SCHEMBL9252798 | 0.77 | HRH1 (0.48) | — | |
| SCHEMBL31232816 | 0.76 | ADRA1D (0.71) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7259173-B2 | Derivatives of 3-phenyl-n-(2-(4-benzyl)-piperidin-1-yl)-ethyl)-acrylamid with ccr-3-receptor antagonistic activity for use in the treatment of inflammations and allergic conditions | NOVARTIS AG (CH) | 2007-08-21 | — | — | US | disclosed |
| EP-1401814-B1 | DERIVATIVES OF 3-PHENYL-N-(2- (4-BENZYL) PIPERIDIN-1-YL)-ETHYL)-ACRYLAMID WITH CCR-3 RECEPTOR ANTAGONISTIC ACTIVITY FOR USE IN THE TREATMENT OF INFLAMMATIONS AND ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2006-09-06 | — | — | EP | disclosed |
| US-20040180926-A1 | Derivatives of 3-phenyl-n-(2-(4-benzyl)-piperidin-1-yl)-ethyl)-acrylamid with ccr-3-receptor antagonistic activity for use in the treatment of inflammations and allergic conditions | NOVARTIS AG (CH) | 2004-09-16 | — | — | US | disclosed |
| EP-1401814-A1 | DERIVATIVES OF 3-PHENYL-N-(2- (4-BENZYL) PIPERIDIN-1-YL)-ETHYL)-ACRYLAMID WITH CCR-3 RECEPTOR ANTAGONISTIC ACTIVITY FOR USE IN THE TREATMENT OF INFLAMMATIONS AND ALLERGIC CONDITIONS | Novartis AG (CH) | 2004-03-31 | — | — | EP | disclosed |
| WO-2002102775-A1 | DERIVATIVES OF 3-PHENYL-N-(2- (4-BENZYL) PIPERIDIN-1-YL)-ETHYL)-ACRYLAMID WITH CCR-3 RECEPTOR ANTAGONISTIC ACTIVITY FOR USE IN THE TREATMENT OF INFLAMMATIONS AND ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180926-A1 | Derivatives of 3-phenyl-n-(2-(4-benzyl)-piperidin-1-yl)-ethyl)-acrylamid with ccr-3-receptor antagonistic activity for use in the treatment of inflammations and allergic conditions | CCR1, CCR3, CCR4 | ACHE 3679/4885SLC6A2 4627/4885SLC6A4 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.